Paduchová Zuzana, Nagyová Zuzana, Wang Duolao, Muchová Jana
Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia.
JuvenaliaA Paediatric Centre, 929 01 Dunajská Streda, Slovakia.
Nutr Res Pract. 2024 Feb;18(1):98-109. doi: 10.4162/nrp.2024.18.1.98. Epub 2023 Dec 1.
BACKGROUND/OBJECTIVES: The efficacy of Lab4 probiotic and vitamin C combination on the prevention of upper respiratory tract infections (URTIs) was investigated in two studies with children. Our objective was to pool dataset of 57 preschool children from the PROCHILD study (ISRCTN28722693) and the dataset of 50 preschool matched cohort from the PROCHILD-2 study (ISRCTN26587549) to evaluate the impact of probiotic/vitamin C combination on the prevention of upper respiratory tract symptoms and provide a more robust assessment of effect using detailed individual level data.
SUBJECTS/METHODS: The children were supplemented daily for 6 months with either the multistrain probiotic (1.25×10 cfu/tablet consisting of two strains of CUL21 and CUL60, CUL20 and subsp. CUL34) plus 50 mg vitamin C or a placebo.
In the pooled analysis of the individual participant data (per protocol population), significant reductions were observed for the incidence (-25%; 95% confidence interval [CI], 0.66, 0.85; < 0.0001) and duration (-14.9 days; 95% CI, -24.8, -5.1; = 0.0030) of typical URTI symptoms in the active group compared with the placebo. The incidence rates of absenteeism from preschool (IR ratio, 0.75; 95% CI, 0.66, 0.86; < 0.0001), paediatric visits (IR ratio, 0.56; 95% CI, 0.47; 0.68; < 0.0001) and antibiotic usage (IR ratio, 0.53; 95% CI, 0.39, 0.71; < 0.0001) were also significantly reduced.
The pooled analysis findings of comparable preschool cohorts from two studies indicate that the supplementation with probiotic and vitamin C combination is beneficial in the prevention and management of URTI symptoms.
背景/目的：在两项针对儿童的研究中，对Lab4益生菌与维生素C联合使用预防上呼吸道感染（URTI）的效果进行了调查。我们的目标是汇总来自PROCHILD研究（ISRCTN28722693）的57名学龄前儿童的数据集以及来自PROCHILD - 2研究（ISRCTN26587549）的50名学龄前匹配队列的数据集，以评估益生菌/维生素C联合使用对预防上呼吸道症状的影响，并使用详细的个体水平数据对效果进行更可靠的评估。
受试者/方法：这些儿童每天补充6个月的多菌株益生菌（每片含1.25×10 cfu，由CUL21和CUL60、CUL20以及亚种CUL34两种菌株组成）加50毫克维生素C或安慰剂。
在个体参与者数据的汇总分析（符合方案人群）中，与安慰剂相比，活性组典型URTI症状的发生率（-25%；95%置信区间[CI]，0.66，0.85；P<0.0001）和持续时间（-14.9天；95% CI, -24.8, -5.1；P = 0.0030）显著降低。学龄前缺勤率（发病率比，0.75；95% CI，0.66，0.86；P<0.0001）、儿科就诊率（发病率比，0.56；95% CI，0.47；0.68；P<0.0001）和抗生素使用率（发病率比，0.53；95% CI，0.39，0.71；P<0.0001）也显著降低。
两项研究中可比的学龄前队列的汇总分析结果表明，补充益生菌和维生素C联合使用对上呼吸道感染症状的预防和管理有益。
